Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Vertex Pharmaceuticals Incorporated (VRTX) Operating cash flow
Vertex Pharmaceuticals Incorporated's operating cash flow for fiscal 2025 was $3.6B, compared with −$492.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.3B. Over the past ten years it has ranged from −$492.6M (fiscal 2024) to $4.1B (fiscal 2022); the current reading is higher than 91% of that period. Vertex Pharmaceuticals Incorporated ranks 2nd of 613 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Annual
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $3.6B | — |
| FY2024 | −$492.6M | — |
| FY2023 | $3.5B | (14.35%) |
| FY2022 | $4.1B | 56.23% |
| FY2021 | $2.6B | (18.75%) |
| FY2020 | $3.3B | 107.32% |
| FY2019 | $1.6B | 23.54% |
| FY2018 | $1.3B | 50.34% |
| FY2017 | $844.9M | 257.87% |
| FY2016 | $236.1M | — |
Quarterly
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $1.1B | (21.20%) |
| Mar 2026 | $1.4B | 186.77% |
| Dec 2025 | $498.0M | (59.88%) |
| Sep 2025 | $1.2B | 15.68% |
| 42 more quarters | Free account |
Against its own ten years
Low −$492.6M
High $4.1B
Ten-year median
$1.6B
Current reading's percentile
91
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $4.7B |
| VRTX Vertex Pharmaceuticals Incorporated | $4.3B |
| RPRX Royalty Pharma PLC compare | $3.0B |
| ARGX argenex SE compare | $1.6B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.5B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $911.8M |
| INSM Insmed, Inc. compare | −$778.9M |
| MRNA Moderna, Inc. compare | −$1.1B |
| RVMD Revolution Medicines, Inc. compare | −$1.2B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement